Search

Background: Previous studies to determine the cost of haemodialysis (HD) in Spain have significant limitations: they are outdated or used indirect methods. There is also a lack of analysis performed simultaneously on Public centres (PC), with direct HD services, and partially state-subsidised centres (SC). This is an important issue since the two systems coexist in Spain., Objectives: To estimate the cost of HD replacement therapy for chronic renal failure in several centres., Methods: This is a prospective and publicly-funded study, which estimates the costs for 2008 using a cost accounting system with specific allocation criteria. We collected demographic and comorbidity data for each centre., Results: Six centres participated, two PC and four SC. There were no significant differences between centres in terms of patient demographics, time on haemodialysis and the Charlson comorbidity index. The total cost per patient per year ranged between € 46, 254 and € 33,130. The cost per patient per year (excluding vascular access and hospital admission) for PC was € 42, 547 and € 39, 289 and for SC € 32 872, € 29, 786, € 35, 461 and € 35, 294 (23% more in PC than SC). Costs related to staff/patient/year and consumables/patient/year were 67% and 83% respectively, higher for PC than SC. The highest percentage cost was for staff (average 30.9%), which showed significant variability between centres, both in absolute numbers (staff cost per patient per year between € 18,151 and € 8504) and as a percentage (between 42.6 % and 25.4%)., Conclusions: Cost variability exists among different HD centres, and this can be attributed primarily to staff and consumables costs, which is higher for PC than SC.

Four experiments were done to determine: (1) the effectiveness of early detection and treatment of vesiculitis in bulls; (2) whether antibiotic treatment at recommended dosages will result in adequate vesicular gland tissue concentrations of antibiotics to prevent in vitro bacterial growth; (3) whether intraglandular injection of antibiotics can be a successful alternative to systemic antibiotic treatment; and (4) the effectiveness of tilmicosin versus tulathromycin for treatment of clinical vesiculitis. In Experiment 1, there was a high rate of spontaneous remission from vesiculitis detected at 9-12 mo of age. Furthermore, there was no advantage for early antibiotic treatment versus no treatment for bulls of this age. In Experiment 2, bacteria on agar plates were exposed to fluid extracted from vesicular gland biopsies after antibiotic treatment of normal, healthy bulls. Although inadequate concentrations of antibiotics were achieved to inhibit bacterial growth when recommended dosages of various antibiotics were administered, doubling the antibiotic dosage increased in vitro bacterial growth inhibition. In Experiment 3, relatively nonirritating antibiotics were injected directly into the glands of bulls with clinical vesiculitis, demonstrating that intraglandular injections of antibiotic could be used as a successful alternative to systemic antibiotic treatment. Experiment 4 was a clinical field trial to compare the efficacy of tilmicosin versus tulathromide at recommended dosages for the treatment of clinical vesiculitis. Although the results favored tulathromycin, both antibiotics resulted in clinical cures of vesiculitis.

The effects of estradiol-17beta (E-17beta) or estradiol benzoate (EB) on gonadotrophin release, estrus and ovulation in beef cattle were evaluated in two experiments. In experiment 1, 16 ovariectomized cows received a previously used CIDR insert from days 0 to 7 and 1mg of EB on day 8; they also received 5mg of E-17beta on days 0 or 1, or 5mg of E-17beta+100mg of progesterone on day 0. There was only an effect of time (P<0.0001) on plasma concentrations of progesterone, estradiol, FSH, and LH. Following treatment with E-17beta, plasma FSH concentrations were suppressed for approximately 36 h, whereas plasma LH concentrations were reduced (P<0.05) for 6 h, but surged within 24 h. Injecting 1mg of EB 24 h after CIDR removal decreased (P<0.02) plasma LH concentrations for 6h, followed by an LH surge at 18 h. In experiment 2, ovary-intact heifers (n=40) received a used CIDR and 5mg of E-17beta+100mg of progesterone on day 0. On day 7, CIDR were removed, PGF given, and heifers received nothing (control) or 1mg of EB 12, 24, or 36 h later. In these groups, plasma LH peaked (mean+/-SEM) 78.0+/-23.0, 37.8+/-8.5, 44.4+/-10.3, and 51.0+/-5.1 h after CIDR removal (means, P<0.001; variances, P<0.001) and intervals from CIDR removal to ovulation were 102.0+/-6.7, 63.6+/-3.6, 81.6+/-3.5, and 78.0+/-4.1h (P<0.05). The interval from CIDR removal to ovulation was shorter and less variable in EB-treated groups; the interval from EB to ovulation was shortest (P<0.05) in the 12-h group. In summary, E-17beta or EB decreased both FSH and LH, but LH increased after 6h (despite elevated progesterone concentrations). Following CIDR removal, 1mg of EB effectively synchronized LH release, and ovulation (in intact cattle), but the interval from CIDR removal to EB treatment affected the time of ovulation.

Three experiments evaluated the effects of estradiol valerate (EV) on ovarian follicular and CL dynamics, intervals to estrus and ovulation, and superovulatory response in cattle. Experiment 1 compared the efficacy of two norgestomet ear implants (Crestar and Syncro-Mate B; SMB) for 9 d (with PGF at implant removal), combined with either 5 mg estradiol-17beta and 100 mg progesterone (EP) or 5 mg EV and 3mg norgestomet (EN) im at the time of implant insertion on CL diameter and follicular wave dynamics. Ovaries were monitored by ultrasonography. There was no effect of norgestomet implant. Diameter of the CL decreased following EN treatment (P < 0.01). Mean (+/- S.D.) day of follicular wave emergence (FWE) was earlier (P < 0.0001) and less variable (P < 0.0001) in EP- (3.6 +/- 0.5 d) than in EN- (5.7 +/- 1.5 d) treated heifers. Intervals from implant removal to estrus (P < 0.001) and ovulation (P < 0.01) were shorter in EN- (45.7 +/- 11.7 and 74.3 +/- 12.6 h, respectively) than in EP- (56.4 +/- 14.1 and 83.3 +/- 17.0 h, respectively) treated heifers. Experiment 2 compared the efficacy of EP versus EN in synchronizing FWE for superovulation in SMB-implanted cows. At random stages of the estrous cycle, Holstein cows (n = 78) received two SMB implants (Day 0) and were randomly assigned to receive EN on Day 0 or EP on Day 1. Folltropin-V treatments were initiated on the evening of Day 5, with PGF in the morning and evening of Day 8, when SMB were removed. Cows were inseminated after the onset of estrus and embryos were recovered 7 d later. Non-lactating cows had more CL (16.7 +/- 11.3 versus 8.3 +/- 4.9) and total ova/embryos (14.7 +/- 9.5 versus 7.9 +/- 4.6) than lactating cows (P < 0.05). EP-treated cows tended (P = 0.09) to yield more transferable embryos (5.6 +/- 5.2) than EN-treated cows (4.0 +/- 3.7). Experiment 3 compared the effect of dose of EV on ovarian follicle and CL growth profiles and synchrony of estrus and ovulation in CIDR-treated beef cows (n = 43). At random stages of the estrous cycle (Day 0), cows received a CIDR and no further treatment (Control), or an injection of 1, 2, or 5 mg im of EV. On Day 7, CIDR were removed and cows received PGF. Follicular wave emergence occurred within 7 d in 7/10 Control cows and 31/32 EV-treated cows (P < 0.05). In responding cows, interval from treatment to FWE was longer (P < 0.05) in those treated with 5 mg EV (4.8 +/- 1.2 d) than in those treated with 1 mg (3.2 +/- 0.9 d) or 2 mg (3.4 +/- 0.8 d) EV, while Control cows were intermediate (3.8 +/- 2.0 d). Diameter of the dominant follicle was smaller (P < 0.05) at CIDR removal and tended (P = 0.08) to be smaller just prior to ovulation in the 5 mg EV group (8.5 +/- 2.2 and 13.2 +/- 0.6 mm, respectively) than in the Control (11.8 +/- 4.6 and 15.5 +/- 2.9 mm, respectively) or 1mg EV (11.7 +/- 2.5 and 15.1 +/- 2.2 mm, respectively) groups, with the 2mg EV group (10.7 +/- 1.5 and 14.3 +/- 1.7 mm, respectively) intermediate. Diameter of the dominant follicle at CIDR removal was less variable (P < 0.01) in the 2 and 5mg EV groups than in the Control group, and intermediate in the 1mg EV group. In summary, treatment with 5mg EV resulted in a longer and more variable interval to follicular wave emergence than treatment with 5mg estradiol-17beta, which affected preovulatory dominant follicle size following progestin removal, and may have also affected superstimulatory response in Holstein cows. Additionally, 5 mg EV appeared to induce luteolysis in heifers, reducing the interval to ovulation following norgestomet removal. Conversely, intervals to, and synchrony of, follicular wave emergence, estrus and ovulation following treatment with 1 or 2 mg EV suggested that reduced doses of EV may be more useful for the synchronization of follicular wave emergence in progestogen-treated cattle.

The objective was to determine reproductive performance following AI in beef heifers given estradiol to synchronize ovarian follicular wave emergence and estradiol or GnRH to synchronize ovulation in a two-dose PGF-based protocol. In Experiment 1, 561 cycling (confirmed by ultrasonography), Angus heifers received 500 microg cloprostenol, i.m. (PGF) twice, 14 days apart (days 0 and 14) and were equally allocated to four groups in a 2 x 2 factorial design. On Day 7, heifers received either 2 mg estradiol benzoate (EB) and 50 mg progesterone (P), i.m. in oil (EBP group) or no treatment (NT group). Half the heifers in each group received 1mg EB, i.m. in oil on Day 15 (24h after the second PGF treatment) with TAI 28 h later (52 h after PGF), and the other half received 100 microg GnRH, i.m. on Day 17 (72 h after PGF) concurrent with TAI. All heifers were observed for estrus twice daily from days 13 to 17; those detected in estrus more than 16 h before scheduled TAI were inseminated 4-16 h later and considered nonpregnant to TAI. Overall pregnancy rate (approximately 35 days after AI) was higher in heifers that received EBP than those that did not (61.6% versus 48.2%, respectively; P < 0.002); but was lower in heifers that received EB after PGF than those that received GnRH (50.0% versus 59.8%; P < 0.02). Although estrus was detected prior to TAI in 77 of 279 heifers (27.6%) treated with EBP (presumably due to induced luteolysis), they were inseminated and 53.2% became pregnant. Overall pregnancy rates were 51.4, 68.3, 45.0, and 55.0% in the NT/GnRH, EBP/GnRH, NT/EB, and EBP/EB groups, respectively (P < 0.05). In Experiment 2, 401 cycling, Angus heifers were used. The design was identical to Experiment 1, except that 1.5mg estradiol-17beta (E-17beta) plus 50mg progesterone (E-17betaP) and 1mg E-17beta were used in lieu of EBP and EB, respectively. All heifers receiving E-17beta 24h after the second injection of PGF (NT/E-17beta and E-17betaP/E-17beta) were TAI 28 h later without estrus detection, i.e. 52 h after PGF. Heifers in the other two groups received 100 microg GnRH, i.m. 72 h after PGF and were concurrently TAI; heifers in these two groups that were detected in estrus prior to this time were inseminated 4-12h later and considered nonpregnant to TAI. Estrus rate during the first 72 h after the second PGF treatment was higher (P < 0.05) in the E-17betaP/GnRH group (45.0%; n = 100) than in the NT/GnRH group (16.0%; n = 100), but conception rate following estrus detection and AI was not different (mean, 57.4%; P = 0.50). Overall pregnancy rate was not significantly different among groups (mean, 46.9%; P = 0.32). In summary, the use of EB or E-17beta to synchronize follicular wave emergence and estradiol or GnRH to synchronize ovulation in a two-dose, PGF-based protocol resulted in acceptable fertility to TAI. However, when 2mg EB was used to synchronize follicular wave emergence, early estrus occurred in approximately 28% of heifers, necessitating additional estrus detection. A combination of estrus detection and timed-AI in a two-dose PGF protocol resulted in highly acceptable pregnancy rates.

The objectives were to determine pregnancy rates following fixed-time AI (FTAI) in heifers: (1). given GnRH or estradiol cypionate (ECP) to synchronize follicular wave emergence and ovulation in a CIDR-based protocol; and (2). fed diets supplemented with flax or sunflower seeds. At two locations, Angus and crossbred Angus heifers (n=983) were examined ultrasonically to confirm reproductive maturity and randomly allocated to six synchronization groups in a 2 x 3 factorial design. On Day 0 (start of synchronization treatments), heifers received a CIDR and either 100 microg GnRH i.m. (n=492) or 1mg ECP plus 50 mg progesterone i.m. (n=491); in these groups, CIDR removal and PGF treatment were done concurrently on Days 7 and 8.5, respectively. Heifers were re-randomized to receive 0.5 mg ECP i.m. at CIDR removal or 24 h later (with FTAI 58-60 h after CIDR removal in both groups), or 100 microg GnRH i.m. concurrent with FTAI (52-54 h after CIDR removal). The heifers were fed a barley silage-based diet for 50 days (from Day -25 to 25) supplemented with 1kg/heifer per day of flax seed (n=321), sunflower seed (n=324), or no oilseed (n=338). Pregnancy rate to FTAI (overall, 56.2%) was not affected by treatment at CIDR insertion (P = 0.96) but was higher (P < 0.05) in heifers given ECP 24h after CIDR removal (216/330, 65.4%) than in those given either ECP at CIDR removal (168/322, 52.1%) or GnRH at AI (169/331, 51.1%). Overall, there was no effect of diet on pregnancy rates (P = 0.46). In summary, pregnancy rate to FTAI was not significantly affected by treatment at CIDR insertion to synchronize follicular wave emergence, but 0.5mg ECP 24h after CIDR removal (to synchronize ovulation) resulted in the highest pregnancy rate.

Ultrasonography has been shown to be a useful tool for pregnancy diagnosis and the study of embryonic growth in mammals. The objectives of this study were 1) to evaluate the use of real-time B-mode ultrasonography for early pregnancy diagnosis in goats, 2) to define criteria for accurate diagnosis of pregnancy, and 3) to monitor the embryonic growth ultrasonically until Day 40 after mating. Estrus was synchronized in 16 cyclic Anglo-Nubian goats with a single injection of cloprostenol (125 micrograms, i.m.). Estrous females were randomly assigned into 2 groups: 1) goats mated by a vasectomized male (n = 5; MV group), and 2) goats mated by an intact male of proven fertility (n = 11; MF group). Transrectal ultrasonographic examinations with a 5 MHz linear array transducer were performed from Days 13 to 40 post mating. The evaluated parameters included the appearance of nonechogenic areas in the uterus, presence of embryo(s), crown-rump length of embryo and embryonic heart rate (beats/min). On Day 18, the mean (+/- SEM) diameter of nonechogenic areas was 1.5 +/- 0.3 mm in the MV group and 4.0 +/- 0.5 mm in the MF group (P < 0.01). In 36% of the pregnant does these areas were less than 3 mm. The mean (+/- SEM) day of the first detection by means of heartbeats of at least 1 embryo was 20.7 +/- 0.5 d (range, Days 19 to 23). From Days 19 to 38 of pregnancy, crown-rump length was best represented by a linear regression (Y = -2.23 + 0.13X; r2 = 0.94; P < 0.05). Crown-rump length on the day of the first detection of an embryo was 5.3 +/- 0.3 mm, reaching 34.2 +/- 0.6 mm on Day 40. Mean (+/- SEM) heartbeat rate was 168.3 +/- 2.8 beats/min on Day 21, decreasing to 158.3 +/- 2.0 beats/min on Day 40. Detection of the caprine embryo by ultrasonography and confirmation of its viability by heartbeats was shown to be a reliable method for early pregnancy diagnosis in Anglo-Nubian goats. Ultrasonic measurement of crown-rump length was useful in predicting the age of the embryo.